Samsung Bioepis Moves Swiftly To Denosumab Phase III
SB16 Biosimilar Rival To Prolia Progresses To Phase III Trials
Executive Summary
Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.
You may also be interested in...
Lupin Liquidating Japan JV With Yoshindo, Partners With I’Rom For Denosumab Biosimilar
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
Lupin Liquidating Japan JV With Yoshindo, Partners I’Rom For Denosumab Biosimilar
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars
In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.